Find policies, billing codes, payers, states, and providers
Omalizumab Products (Xolair, Omlyclo) coverage
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.513 alerts
Get alerted when Policy 5.01.513 changes without checking for updates manually.
Monitor payer policy activity
This policy defines medical necessity, site-of-service review, documentation, coding, and approval durations for omalizumab products (Xolair and Omlyclo) across indications including moderate-to-severe asthma, chronic idiopathic urticaria, CRSwNP, and IgE-mediated food allergy; it applies to providers submitting pharmacy or medical benefit requests to Premera Bluecross.
Updated initial authorization for all reviews from 6 months to 12 months.
Updated indication for asthma to add Exdensur (depemokimab-ulaa) to list of medications not to be used concurrently.
Updated chronic idiopathic urticaria dose limit to 600 mg every 2 weeks.
Updated asthma criteria to use maximum tolerated doses of an inhaled corticosteroid instead of maximum doses.
Updated asthma diagnostic criteria to include two or more exacerbations in previous 12 months requiring oral corticosteroids, or one or more exacerbations requiring hospitalization/ED/urgent care, or FEV1 <80% predicted, or dependence on oral corticosteroids/worsening on taper.
Policy title updated from Xolair (omalizumab) to Omalizumab Products and Omlyclo (omalizumab-igec) was added with the same criteria as Xolair.
Coverage Criteria for Omalizumab Products
Moderate to severe persistent allergic asthma (site-of-service criteria applied)
Covered when ALL of the following are met
Site-of-service review may apply
Severe chronic idiopathic urticaria
Covered when ALL of the following are met
Chronic rhinosinusitis with nasal polyps (CRSwNP)
Covered when ALL of the following are met
IgE-mediated food allergy (to reduce Type I allergic reactions)
Covered when ALL of the following are met
Asthma — general positioning: adjunct for moderate to severe allergic asthma inadequately controlled despite standard therapies
Covered when used as an adjunct for individuals with moderate to severe allergic asthma inadequately controlled despite standard therapies
Positioning based on rationale and trial data
Chronic Idiopathic Urticaria (CIU) — trial eligibility-like criteria supported by CIU trials
Covered when trial eligibility-like criteria are met as supported by CIU trials
Derived from CIU pivotal trials
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) — trial-like criteria reflecting inadequate response to intranasal corticosteroids
Covered when trial-like criteria reflecting inadequate response to intranasal corticosteroids are met
Background nasal mometasone required in trials
IgE-mediated Food Allergy (supportive evidence)
Covered stance informational — supportive randomized trial data in multi-food allergic individuals
Supportive evidence for select use cases
Asthma - Initial Therapy
Coverage is provided when indication-specific clinical criteria and FDA dosing/administration requirements are met; prior therapies and diagnostic thresholds vary by indication.
Concurrent use with certain biologics (e.g., Exdensur/depemokimab-ulaa) is not permitted.
Chronic Idiopathic Urticaria - Initial Therapy
Chronic idiopathic/spontaneous urticaria (CIU/CSU) coverage reflects FDA-labeled indications and trial-based dosing.
Initial approval length updated to 12 months.
Chronic Rhinosinusitis with Nasal Polyps - Initial Therapy
Chronic rhinosinusitis with nasal polyps (CRSwNP) criteria updates.
Must follow FDA dosing/administration.
Combination Therapy Exclusions
Combination therapy exclusions
Requests for concurrent use may be denied.
Coverage and dosing criteria
Coverage and dosing are determined using pretreatment total serum IgE and patient body weight; initial authorization duration is 12 months.
Do not use IgE measured during treatment for dose determination; re-test only if treatment interrupted ≥1 year.
Initial authorization period updated to 12 months.
See chunk 73 for details.
Dosing and administration rules
Covered when dosing and clinical documentation follow product labeling and policy-specific restrictions
Do not use IgE tested during treatment for dose determination; re-test only after interruption >=1 year
CIU dosing ceiling updated in policy rationale; periodically reassess need for therapy
Requests for concurrent use may be denied
Omalizumab is designated investigational for uses not specifically listed as covered in this policy. Examples of indications considered investigational include allergic rhinitis, atopic dermatitis, other IgE‑mediated conditions, latex allergy, and bullous pemphigoid. Requests for these uses do not meet the policy's medical necessity criteria and should be denied unless supported by separate, specific coverage guidance.
For chronic idiopathic urticaria (CIU), the policy notes that the 75 mg dose did not demonstrate consistent evidence of efficacy in pivotal CIU trials and is not an approved or supported dose for this indication. CIU dosing per labeling and policy is 150 mg or 300 mg every 4 weeks, with higher limits and frequency specified elsewhere only when supported by the product information and policy limits.
The policy specifies that omalizumab should not be used in combination with certain other biologic therapies for the same indication. Notably, the policy prohibits concurrent use with tezepelumab (Tezspire/Exdensur/depemokimab-ulaa) when treating asthma and with dupilumab (Dupixent) when treating chronic rhinosinusitis with nasal polyps (CRSwNP). Such concurrent use is outside the policy's coverage rules and may be denied.
The policy explicitly adds Exdensur (depemokimab-ulaa) to the list of agents that must not be used concurrently with omalizumab for the treatment of asthma. Concurrent administration of these agents for the same indication is not allowed under the updated coverage rules.
Operationally, the policy enforces combination‑therapy exclusions across specified biologics. When omalizumab is requested for asthma or nasal polyps, coverage is contingent on not being used concurrently with the listed biologic agents (examples include tezepelumab/Exdensur, depemokimab-ulaa, dupilumab, mepolizumab, and others shown in the policy). Requests that propose simultaneous therapy with these agents for the same indication may be considered not medically necessary.
The policy includes a site-of-service review. Administration in a hospital outpatient department or other non-preferred sites may be considered not medically necessary if the policy's site-of-service criteria are not met (for example, preferred sites, the first 90‑day guidance, distance to an outpatient infusion center, or specific high‑risk clinical conditions).
The evidence and policy rationale reiterate that the 75 mg dose for CIU lacks consistent efficacy and is not supported by the clinical trial data; CIU dosing guidance remains centered on 150 mg or 300 mg every 4 weeks, with the policy's CIU dose ceiling updated to reflect a maximum of 600 mg every 2 weeks where applicable per the policy's revised limits.
Providers must supply documentation that supports the absence of concurrent use with the biologics listed in the policy. Prior authorization and clinical records should explicitly state whether the patient is receiving any of the prohibited agents (for example, tezepelumab, depemokimab-ulaa, dupilumab, mepolizumab, remibrutinib, etc.); failure to document that omalizumab will not be combined with these agents may result in denial.
The asthma dosing tables in the policy include explicit guidance for IgE/weight combinations and incorporate ‘DO NOT DOSE’ entries for certain very high pretreatment total serum IgE and body‑weight ranges (for example, specific >900–1,000 IU/mL ranges), indicating dosing is not recommended for those combinations.
The policy update clarifies that concurrent combination therapy of omalizumab with the listed biologics for the same indication is not appropriate and may be denied. This operational restriction applies to treatment of both asthma and nasal polyps and reflects recent additions to the exclusion list.
Coding and Dose Ranges
| NDCs referenced in PI | Product prescribing information references for Xolair and Omlyclo (NDCs not explicitly listed in this excerpt). |
| J2357 | Omalizumab injection |
Provider Actions, Prior Authorization, and Documentation
Obtain prior authorization; approvals can be up to 12 months
Prior authorization is required for omalizumab products; initial approvals and reauthorizations may be granted for up to 12 months when medical necessity criteria and documentation of clinical response are provided.
- Initial authorizations for all drugs in this policy may be approved up to 12 months.
- Reauthorization for indications (asthma, CIU, CRSwNP, IgE-mediated food allergy) may be approved up to 12 months if medical necessity criteria are met and chart notes document continued clinical response (e.g., reduced exacerbations, improved symptoms, decreased itch/hives, decreased polyp size).
Follow benefit-specific prior authorization and site-of-service rules
Omalizumab may be billed under either the pharmacy or medical benefit depending on the benefit management; prior authorization and administration-site requirements apply according to the benefit used.
- Omalizumab is managed through both the pharmacy and medical benefits.
- Prior authorization is implied where the applicable benefit requires it and site-of-service review may be applied for administration.
Request initial approval (standardized to 12 months) and expect site-of-service review when applicable
Submit prior authorization requests using the policy-required clinical documentation and note that initial approvals are standardized to 12 months and may be subject to site-of-service review.
- Initial approvals standardized to 12 months for all indications.
- Site-of-service review may be applied when applicable (injection drugs subject to site-of-service criteria).
- Providers must demonstrate medical necessity per indication to support a 12-month approval.
Expect 12-month initial authorizations
Initial authorizations for omalizumab are granted for 12 months (policy updated from 6 months); request duration beyond this standard risks denial.
- Policy updated initial authorization period from 6 months to 12 months for all reviews.
- Requests inconsistent with the updated 12-month standard may be subject to denial review.
Ensure administrative requests reflect 12‑month initial authorizations
Prior authorization is required per policy; administrative processes reflect the updated initial authorization length of 12 months for all reviews.
- All drugs in this policy may be approved up to 12 months on initial authorization.
- Operational updates removed non-formulary exception language and standardized authorization length.
Document failure/intolerance to ≥2 high‑dose H1‑antihistamines for CIU
For chronic idiopathic urticaria, document trial and failure or intolerance to at least two H1-antihistamines at high doses (up to 4× normal dosing) before requesting omalizumab.
- Failed or intolerant to at least 2 H1-antihistamines in high doses (at least twice normal dosing and up to 4× normal dosing) or maximum tolerated dose.
- Plan to continue a low dose of H1 antihistamines while on omalizumab.
Justify omalizumab as last‑line add‑on for moderate–severe asthma
Position omalizumab as an add‑on or last‑line option for moderate to severe persistent allergic asthma after optimization of inhaled corticosteroids and other controllers; include documentation of prior therapies.
- Clinical justification should document use of prior standard therapies (inhaled corticosteroid at maximum tolerated dose plus additional controllers as indicated).
- Policy frames omalizumab as an adjunct for individuals inadequately controlled despite these therapies.
Document prior inadequate response to high‑dose H1‑antihistamines for CIU
For CIU, the policy requires documentation of prior inadequate response to high‑dose H1‑antihistamine therapy before omalizumab is approved.
- Provider must document inadequate response to high‑dose H1‑antihistamines.
- CIU dosing must comply with product labeling and not exceed 600 mg every 2 weeks.
Document prior controller therapies per appendix
Include documentation of current controller therapies when requesting omalizumab for asthma (appendix lists relevant inhaled corticosteroids, long‑acting bronchodilators, leukotriene modifiers, and antihistamines).
- Appendix lists inhaled corticosteroids (e.g., fluticasone, budesonide, mometasone), long‑acting bronchodilators (e.g., salmeterol), leukotriene modifiers, and antihistamines.
- Document prior optimization and use of these background controller therapies in the medical record.
Adhere to policy prior‑medication step requirements
Follow the policy's prior medication requirements for CIU and asthma; document prior antihistamine trials for CIU and optimization of inhaled corticosteroids (maximum tolerated dose) for asthma per the current policy.
- Providers must follow the current policy's specified prior medication requirements; earlier policy history documents prior steps but the current policy supersedes those.
- Asthma criteria changed to 'maximum tolerated doses' of inhaled corticosteroids.
- CIU requires prior antihistamine trials as described.
Include complete office visit notes in the medical record submission
Provide office visit notes that include the diagnosis, relevant history, physical exam, and detailed medication history when submitting medical necessity documentation.
- Submit office visit notes documenting the diagnosis, relevant history, physical evaluation and medication history to support medical necessity.
Document ≥3 in‑office doses and anaphylaxis risk assessment before self‑administration
Document that at least three doses were administered in a health care provider's office and include the clinician's assessment of anaphylaxis risk and mitigation strategies before requesting self‑administration.
- Omalizumab must be administered in a provider's office for at least 3 doses to establish safety.
- Provider assessment of risk for anaphylaxis and mitigation strategies must be documented before approving self‑administration.
Provide indication‑specific clinical documentation (exacerbations, FEV1, prior steroids/surgeries)
Include diagnosis‑specific clinical documentation: for asthma, document exacerbation history, FEV1 results and systemic corticosteroid dependence/tapering issues; for CRSwNP document prior systemic steroid use or prior polyp surgery as applicable.
- Asthma: document exacerbation history (e.g., ≥2 exacerbations requiring oral corticosteroids in prior 12 months), FEV1 results (e.g., <80% predicted), or worsening on steroid taper.
- CRSwNP: document prior systemic corticosteroid use in last 2 years, contraindication to systemic steroids, or prior bilateral polyp surgery.
- CIU: document inadequate response to prior antihistamines and duration ≥6 weeks.
Record pretreatment total serum IgE and body weight for asthma dosing
Document pretreatment total serum IgE and body weight used for dose determination for asthma; note that IgE measured during treatment is not valid for dosing decisions unless treatment was interrupted for ≥1 year.
- Dose determination for asthma must be based on pretreatment total serum IgE and body weight using the dosing tables.
- Re‑testing of IgE during treatment cannot be used for dose determination because total IgE remains elevated for up to one year after discontinuation; re‑test only if treatment interrupted ≥1 year.
Provide required dosing documentation (IgE + weight for asthma; CIU dosing independent)
For initial asthma dosing, document the serum total IgE and body weight and reference the policy's IgE/weight‑based dosing tables; for CIU, document that dosing is independent of IgE and weight.
- Asthma: include serum total IgE and body weight and indicate the dose per the dosing table.
- CIU: document that CIU dosing (150 or 300 mg q4w) does not require IgE or weight for dose selection.
- Note re‑testing: use initial pretreatment IgE if interruption <1 year; re‑test only if interruption ≥1 year.
Avoid site‑of‑service denials by meeting policy criteria
Site‑of‑service requests may be denied if the request does not meet the policy's site‑of‑service criteria (preferred outpatient sites, first‑90‑day in‑office requirement, distance/home infusion availability, or increased‑risk clinical conditions).
- Preferred medically necessary sites include physician's office, infusion center, or home infusion when criteria are met.
- Hospital‑based outpatient settings are considered not medically necessary when site‑of‑service criteria are not met.
- First 90 days of therapy or re‑initiation after ≥6 months commonly require office/infusion setting per policy.
Ensure ≥3 in‑office administrations before self‑administration to avoid denial
Failure to administer at least three doses in a provider office before considering self‑administration can trigger benefit management review or denial; document those in‑office administrations.
- Omalizumab must be given in a health care provider's office for at least 3 doses to establish safety prior to self‑administration consideration.
- Document the dates and assessments for those in‑office administrations.
Avoid denials by following 12‑month authorization standard and combination exclusions
Requests may be denied if they conflict with the policy's updated 12‑month standard or with combination‑therapy exclusions (concurrent use with certain biologics is prohibited).
- Denial risk if requested authorization length exceeds the policy's updated 12‑month standard.
- Denial risk if request proposes concurrent use of omalizumab with prohibited biologics (e.g., Tezspire/tezepelumab, Exdensur/depemokimab‑ulaa, Dupixent/dupilumab).
Use only pretreatment IgE (or re‑test after ≥1 year off therapy) for dosing
Do not base dose decisions on IgE tests obtained during omalizumab treatment because total IgE remains elevated for up to one year after discontinuation; use pretreatment IgE for dose determination or re‑test only after ≥1 year off therapy.
- Re‑testing of IgE during treatment cannot be used for dose determination.
- If treatment interrupted for <1 year, use the initial pretreatment IgE for dosing; re‑test for dose determination only after ≥1 year interruption.
Do not combine omalizumab with listed biologics for the same indication
Do not request concurrent use of omalizumab with specified biologics for the same indication; concurrent therapy with agents such as Tezspire (tezepelumab), Dupixent (dupilumab), or Depemokimab/Exdensur may trigger denial.
- Policy explicitly restricts concurrent use with tezepelumab/Tezspire, depemokimab‑ulaa/Exdensur (asthma), and dupilumab/Dupixent (CRSwNP) among others.
- Requests proposing combination biologic therapy for the same indication may be denied.
Background and Product Information
Background: Omalizumab is a recombinant, humanized anti‑IgE monoclonal antibody that binds free IgE and reduces IgE‑mediated allergic responses. It is used as add‑on maintenance therapy in conditions driven by IgE such as moderate‑to‑severe allergic asthma, chronic spontaneous (idiopathic) urticaria unresponsive to antihistamines, chronic rhinosinusitis with nasal polyps (CRSwNP), and in selected cases to reduce Type I reactions in IgE‑mediated food allergy. Coverage, dosing and administration follow FDA prescribing information and the policy's indication‑specific criteria.
Policy Revision History
Policy effective date updated to 2026-08-01 with initial authorization for all reviews changed from 6 months to 12 months; chronic idiopathic urticaria dose limit set to 600 mg every 2 weeks and Exdensur (depemokimab-ulaa) added to asthma concurrency exclusions.
Policy approved July 14, 2026; title changed from Xolair (omalizumab) to Omalizumab Products and Omlyclo (omalizumab-igec) was added with the same criteria as Xolair; site-of-service review added for Omlyclo.
Annual review approved April 14, 2026 updating initial authorization for all reviews from 6 months to 12 months and adding Exdensur (depemokimab-ulaa) to the list of medications not to be used concurrently for asthma.
Policy changes (effective after 90-day provider notification) including addition of site-of-service review applicable to injection drugs became effective October 3, 2025.
Interim review approved August 12, 2025; site-of-service medical necessity criteria clarified to apply to injection drugs.
Interim review approved January 13, 2026 updating CRSwNP criteria and noting it will not be used in combination with Tezspire (tezepelumab) for that indication.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.